☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Pregabalin rejected by SMC

The Scottish Medicines Consortium has rejected Pregabalin (Lyrica®) for use in peripheral neuropathic pain in adults on the NHS in Scotland.

This is the third time the SMC has reviewed pregabalin for nerve pain following a review in March 2005 and a re-submission in September 2005. The result of the re-submission was reported here.

Despite 18 months having passed since the first review the SMC still state that, "Comparative clinical and cost effectiveness have not been demonstrated".

Action: Pregabalin currently has no place in the treatment nerve pain. Conventional therapies, including amitriptyline, carbamazepine and gabapentin, should continue to be used.

Share 'Pregabalin rejected by SMC' by emailShare 'Pregabalin rejected by SMC' on FacebookShare 'Pregabalin rejected by SMC' on TwitterShare 'Pregabalin rejected by SMC' on LinkedInShare 'Pregabalin rejected by SMC' on reddit


No Comments to “Pregabalin rejected by SMC”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.